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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of psychological therapies for people with borderline personality disorder (BPD).
B A C K G R O U N D
Description of the condition
Borderline personality disorder (BPD) is a condition first recog-
nised in the 20th century (Gunderson 2009).Historically, the term
BPD was coined by Adolph Stern to describe a condition in the
’borderland’ between psychosis and neurosis (Stern 1938). Sub-
sequent psychoanalytic contributions (especially that of Kernberg
1975) have reaffirmed this distinction, emphasising that the ca-
pacity to test reality remains grossly intact but is subject to subtle
distortions, especially under stress.
According to current diagnostic criteria, BPD is characterised by
a pervasive pattern of instability in affect regulation, impulse con-
trol, interpersonal relationships, and self-image (APA 2013;WHO
1993). Clinical hallmarks include emotional dysregulation, im-
pulsive aggression, repeated self-injury, and chronic suicidal ten-
dencies (Fonagy 2009; Lieb 2004). Whereas some authors have
suggested that it is a variant of affective disorders (Akiskal 2004),
others claim that it is only the causes of these diseases that partially
overlap in BPD (Paris 2007). Despite the difficulties in defining
and delimiting the condition, BPD is still being widely researched.
Its importance stems from the considerable psychological suffering
of the persons concerned (Stiglmayr 2005; Zanarini 1998), the de-
bilitating functional impairments (Gunderson 2011a; Gunderson
2011b; Niesten 2016; Skodol 2002; Soeteman 2008b), and from
the significant impact it has on mental health services (Cailhol
2015; Hörz 2010; Soeteman 2008a; Tyrer 2015; Zanarini 2004;
Zanarini 2012).
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The definition of BPD in the Diagnostic and Statistical Manual
of Mental Disorders (DSM), Fifth Edition (DSM-5; APA 2013),
Fourth Edition Text Revision (DSM-IV-TR; APA 2000), and
Fourth Edition (DMS-IV; APA 1994) comprises nine criteria that
cover the features mentioned above. At least five criteria should be
met for a definite categorical BPD diagnosis to be made, and four
criteria for probable diagnosis (see Appendix 1). In the alternative
diagnostic classification system of theWorld Health Organization
(WHO), the International Classification of Diseases, which is cur-
rently in its tenth edition (ICD-10; WHO 1993), the relating
condition is referred to as “Emotionally unstable personality dis-
order (F60.3)”, of which there is an impulsive type (F60.30) and
a borderline type (F60.31; see Appendix 2). The latter essentially
overlaps with the DSM-IV definition. There are 10 possible crite-
ria defined, which very closely reflect the DSM criteria, with the
exception of one criterion not included in DSM (“4. Difficulty
in maintaining any course of action that offers no immediate re-
ward”; WHO 1993). Out of 10 possible criteria at least five must
be met, one of which must be “a marked tendency to quarrelsome
behaviour and to conflicts with others, especially when impulsive
acts are thwarted or criticised”.
The prevalence of BPD in the general population is about 1.5%
(Torgersen 2012). In clinical populations, BDP occurs frequently
(Munk-Jørgensen 2010), with studies reporting a prevalence rang-
ing from 9.3% to 46.3% and a mean point prevalence across the
studies of 28.5% (Torgersen 2012). Though BPD is predomi-
nantly diagnosed in women (75%; APA 2000; APA 2013), it is
estimated to be equally frequent in men (Lenzenweger 2007; Ten
Have 2016; Torgersen 2001; Torgersen 2012). BPD commonly
co-occurs with mood disorders, substance use disorder, eating dis-
orders, post-traumatic stress disorder (PTSD), attention-deficit
hyperactivity disorder (ADHD), and is also associated with other
personality disorders (Coid 2006; Lenzenweger 2007; Stepp2012;
Storebø 2014; Tomko 2014). Suicidal behaviour is reported to
occur in up to 84% of people diagnosed with BPD (Goodman
2012; Soloff 2002), and comorbid mood disorders or substance
use disorders are the most common risk factors associated with
successful suicide attempts (Black 2004; Doyle 2016; Yen 2004).
Although the short- to medium-term outcome of BPD is poor,
there is some evidence that long-term follow-ups show a more
favourable course, with remission rates of about 85% to 88%
within 10 years (Gunderson 2011b; Zanarini 2007). Here, how-
ever, remission only means that diagnostic criteria are not ful-
filled and does not indicate the absence of any symptoms. Indeed,
whereas acute symptoms - such as self-mutilation, help-seeking
suicide threats or attempts and impulsivity - in most cases de-
crease with time, affective symptoms reflecting areas of chronic
dysphoria, such as chronic feelings of emptiness, intense anger or
profound abandonment, largely remain (Zanarini 2007). There-
fore the majority of people with BPD still have significant levels
of symptoms and experience severe and persistent impairment in
social functioning (Kongerslev 2015; Ng 2016). Risk factors for a
poorer, long-term outcome are comorbid substance use disorders,
PTSD, and anxiety cluster disorders (Zanarini 2005; Zanarini
2007), as well as a family history of psychiatric disorder (especially
mood disorders and substance use disorders), demographic issues
such as older age, longer treatment history, pathological childhood
experiences, temperament issues and adult psychosocial function-
ing (Chanen 2012; De Fruyt 2014; Kongerslev 2015; Zanarini
2007). It is estimated that about 60% to 78% of people diag-
nosed with BPD attempt suicide (Links 2009), though the rate of
completed suicides is far less. Zanarini and colleagues found sui-
cide rates of 4.5% during a 16-year follow-up (Zanarini 2015b),
whereas Stone 1993 reported a suicide rate of 8.5% after 16.5
years. Study estimates of the lifetime risk of suicide among people
diagnosed with BPD range from 3% to 10% (Links 2009).
People with BPDhave difficulties achieving andmaintaining voca-
tional and social functioning over time (Zanarini 2010). Further-
more, treatment-seeking people with personality disorders, such as
BPD, pose a high economic burden on society (van Asselt 2007).
Effective treatments could potentially decrease the high costs as-
sociated with the condition (Soeteman 2008a).The problem of
deliberate self-harm is also a particular issue within this group
(Ayodeji 2015; Kongerslev 2015; Linehan 1997; Rossouw 2012).
In medical settings, people diagnosed with BPD often present af-
ter self-harming behaviour or in suicidal crisis and are treated in
emergency settings, often involving repeated psychiatric hospital-
isations (Cailhol 2015).
In summary, BPD is a condition that has been extensively studied.
It has a major impact on health facilities as those affected often
present in crisis. Recovery from symptoms or functional impair-
ment (or both) was previously considered likely for only a low per-
centage of people diagnosed with BPD. However, the long-term
course, in terms of symptomatic recovery, is favourable (Zanarini
2012). Nonetheless, people diagnosed with BPD continue to have
considerable interpersonal and functional problems, and sustain-
able recovery appears difficult to attain (Biskin 2015; Kongerslev
2015; Rossouw 2012).
Description of the intervention
About three quarters of people with BPD present to mental health
care professionals (Tomko 2014), and they are even more likely to
do so than people with mood, anxiety, or other personality disor-
ders (Ansell 2007). Most will receive psychological interventions
(Goodman 2010; Tomko 2014), and often for relatively long pe-
riods of time (e.g. for a period of one year or longer) (Ansell 2007;
Zanarini 2015a).
A broad range of therapies exist for BPD.The therapy can be either
individual or in a group, or a combination of these two treatment
modalities. As for most other mental disorders, the psychological
interventions can be based on the traditional, major psychother-
apeutic schools, such as psychodynamic psychotherapy, cognitive
behaviour therapy (CBT) or client-centered/humanistic therapy.
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In addition, several specific treatment approaches have been devel-
oped within recent decades to meet the challenges of BPD treat-
ment (Bateman 2015). These disorder-specific approaches are usu-
ally precisely structured and manualised (Bateman 2015). Strate-
gies are provided for addressing interpersonal challenges, such as
emotional dysregulation and impulsivity, which are core problems
for people diagnosed with BPD and could lead to difficulties in
forming a therapeutic alliance. Most BPD-specific psychological
interventions involvemultimodal therapy, treatment contracts, ac-
tively taking measures to minimise premature non-completion of
treatment, providing a crisis intervention protocol and encourag-
ing the patients’ sense of agency (Bateman 2015; Clarkin 2012;De
Groot 2008; Kongerslev 2015; Livesley 2012; Weinberg 2011).
They are typically highly focused on affect and the therapeutic
relationship, with a relatively active therapist implementing inter-
ventions within a supportive and validating atmosphere (Bateman
2015; Clarkin 2012; De Groot 2008; Kongerslev 2015; Livesley
2012; Weinberg 2011).
Among the specific psychological interventions for people diag-
nosed with BPD, the most commonly used are: transference-
focused therapy (Clarkin 1999; Yeomans 2015), mentalisation-
based treatment (Bateman 2004; Bateman 2006; Bateman 2016),
dialectical behaviour therapy (Linehan 1993; Linehan 2015), cog-
nitive analytic therapy (Chanen2014;Ryle1997), schema-focused
therapy (Arntz 2009; Young 2003), and the systems training for
emotional predictability and problem solving (Black 2009). Most
of these treatments are designed as outpatient treatments of 6 to
24 months duration with 1- or 2-weekly individual sessions. Some
also include additional group therapy sessions, inpatient or day-
hospital therapeutic community treatment and psychoeducation.
Broadly speaking, psychodynamic therapies aim to help their pa-
tients understand and reflect on their inner mental processes and
make links between their past and current difficulties. Treatments
based on CBT place emphasis on self-directed learning processes:
patients are encouraged to identify their core beliefs, evaluate and
modify their behaviour accordingly, and gain new experiences.
Dialectical behavioural therapy (DBT; Linehan 1993) is a com-
plex psychological therapy that was developed using some of
the principles of CBT in combination with mindfulness-based
and Zen-Buddhistic and dialectical thinking strategies. It aims to
change behaviour and enhance the ability to tolerate difficult or
painful feelings by focusing on improving skills in stress tolerance,
emotion regulation, interpersonal behaviour, and mindfulness.
Mentalisation-based therapy (Bateman 2004; Bateman 2016)
is a complex psychodynamic and attachment-based psychological
therapy programme that aims to increase the reflective functioning
or mentalising capacity of the individual, helping the person to
understand and recognise the feelings they evoke in others and
the feelings they experience themselves, as well as improving the
capacity for emotion regulation in interpersonal relations.
Schema-focused therapy (SFT; Young 2003) draws from both
cognitive-behavioural and psychoanalytic theories and helps peo-
ple with BPD to identify their self-defeating core themes arising
from unmet emotional needs in childhood and presenting as mal-
adaptive coping styles in adulthood. The goal of SFT is to aid
patients in getting their needs met in adaptive ways.
Transference-focused psychotherapy (TFP; Clarkin 1999)
strives to achieve integrated representations of self and others,
modification of primitive defence operations, and resolution of
identity diffusion by analysis of the transference within the ther-
apeutic relationship. Primitive object relations, which can be po-
larised and split, may be transformed to advanced or mature object
relations characterised by more integrated object relations. TFP
relies on techniques of clarification, confrontation and transfer-
ence interpretation within the relationship between patient and
therapist.
Cognitive analytic therapy (Ryle 1997) assumes that people with
BPD typically experience rapid switching from one self-state to
another in a dissociate manner. The aim is to work with the pa-
tient cognitively to identify procedural sequences, chains of events,
emotions, thoughts and motivations to understand how a target
problem (like self-harm) is established and maintained, and to
identify reciprocal roles (i.e. how early experiences are replayed
later in life).
The systems training for emotional predictability and prob-
lem solving (Black 2009) combines group-based psychoeducation
with skills training, and targets biased social cognition driven by
cognitive filters or schemas.
Relaxation techniques and patient education programmes will be
considered their own intervention class (i.e. not CBT or psycho-
analytically based), as long as they are not explicitly grounded in
or taken from a specific treatment approach (such as psychoeduca-
tion according to the DBT approach, CBT, or the SFT approach,
etc.).
How the intervention might work
Evidence-based psychological therapies are based on assumptions
about causality, core symptoms, and maintenance of the disorder
(Kazdin 2004; Livesley 2003; Livesley 2004). The various psy-
chotherapeutic approaches to BPD claim different mechanisms of
action according to their respective models of disease causation
(Huprich 2015; Livesley 2004; Livesley 2016). However, they also
contain a number of common elements that can account for why
a number of seemingly different approaches appear to be effective
in ameliorating BPD symptoms (Bateman 2015; Fonagy 2014;
Kongerslev 2015; Weinberg 2011), including: a clear and highly
structured treatment framework; an explicit model of BPD symp-
tomatology; a consistent focus on the therapeutic relationship, af-
fect regulation, tolerance of emotional states, and biases in social
cognition; a high priority given to self-harm and suicidal behavior;
active therapists who deliver both support and validation as well as
explorative and change-oriented interventions; mix of treatment
formats (e.g. includes both individual and group therapy); and
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therapist support in the form of supervision and regular meetings.
Following Weinberg 2011:
1. ’emotional dysregulation’ (e.g. intense anger and affective
instability) is addressed through attention to affect, including
raising awareness of emotional states, their triggers, and
enhancing tolerance and regulative strategies;
2. ’behavioral dysregulation’ (e.g. impulsivity, self-harm and
suicidal behaviours) is addressed through change-oriented
interventions including, for example, challenging negative
thoughts, skills training, behavioral experiments, praise, and
limit setting; and
3. ’interpersonal dysfunction’ (e.g. unstable relationships and
stress-related paranoid ideation) is treated using interventions
that enhance the social-cognitive (or mentalising) capacities of
the BPD patient, through making basic and often negatively
biased automatic assumptions explicit and more realistic or
adaptive, and through paying attention to the establishment and
maintenance of a safe and sound working alliance within the
therapy sessions.
There is a risk that psychological therapies might not be help-
ful for all patients, either due to the interventions delivered or
through factors in the relationship between the patient and ther-
apist (Kongerslev 2015; Lilienfeld 2007; Parry 2016), and very
little research has been done on this in patients with BPD. The
effectiveness of the therapy depends on the skills of the therapist
to create the possibility for change with each patient. There is,
therefore, the added complexity that the relationship or working
alliance between the therapist and the patient is itself an ‘active
ingredient’ of the therapy and that the quality of this relationship
is an important predictor of outcome (Horvath 2011; Norcross
2011). There is no guarantee that the therapy will deliver what was
specified in the manual or what was investigated in a randomised
clinical trial (Parry 2016).
Finally, it should be noted that the highly structured treatment
organisation, including regular meetings between staff to discuss
patients as well as supervision and managerial support to staff,
is presumably important not only for the provision of effective
psychological therapy for persons diagnosed with BPD, but also
in order to prevent iatrogenic harm (Hutsebaut 2012).
Why it is important to do this review
People with BPD and their family and friends experience high
levels of psychological suffering. Moreover, BPD is associated with
considerable social costs in terms of service use (e.g. presentation
to emergency clinics due to self-harm or suicidal crises and re-
peated hospitalisations) and poor psychosocial functioning (e.g.
inability to complete education or get/maintain a job). Against
this background, identification of effective psychological therapies
for BPD is important.
Our review aims to provide a systematic summary of the evidence
from randomised controlled trials (RCTs) in order to help people
with BPD, their family and friends, mental health care workers,
and policy and decision managers in general, to make informed
decisions about evidence-based treatment for BPD.
This is a protocol for an update of the two previous Cochrane Re-
views on psychological therapies for BPD (Binks 2006; Stoffers-
Winterling 2012). In addition to updating the former Cochrane
Reviews, our study also seeks to address some of methodologi-
cal limitations of both past and current reviews (Bateman 2015;
Cristea 2017; Kliem 2010), by publishing a protocol for our re-
view and using a broad and updated search strategy.
O B J E C T I V E S
To assess the beneficial and harmful effects of psychological ther-
apies for people with borderline personality disorder (BPD).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Patients of all ages, in any setting, with a formal diagnosis of BPD
according to theDiagnostic and Statistical Manual of Mental Disor-
ders (DSM) Third Edition (DSM-III; APA 1980), Third Edition
Revised (DSM-III-R; APA 1987), Fourth Edition (DSM-IV; APA
1994), Fourth Edition Text Revision (DSM-IV-TR; APA 2000),
and Fifth Edition (DSM-5; APA 2013), with or without comorbid
conditions.
To meet our inclusion criterion, at least 70% of study participants
will have to have a formal diagnosis of BPD. We will also include
studies involving subsamples of BPD patients provided that data
on these patients are available separately (we will ask for separate
data from trials including less than 70% BPD participants). We
will not include studies that focus on people with mental impair-
ment, organic brain disorder, dementia or other severe neurologic/
neurodevelopmental diseases, should there be any.
Types of interventions
Any defined psychological intervention, regardless of theoretical
orientation (e.g. psychodynamic therapy, CBT, systemic therapy
or eclectic therapies designed for BPD treatment), in any kind of
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treatment setting (e.g. inpatient, outpatient or day clinic), com-
pared to:
1. unspecific control interventions/optional use such as
standard care, treatment as usual (TAU) or waiting list (the first
two can be combined in a meta-analysis as different forms of
TAU, with a subgroup analysis investigating the statistical
heterogeneity; see Subgroup analysis and investigation of
heterogeneity);
2. specific psychotherapeutic interventions (well-defined and
theory-driven); and
3. unspecific control interventions/obligatory use (e.g.
community treatments, clinical management, general
management, general psychiatric management; Links 2015).
Unspecific controls include conditions where a patient is free to
use any treatment (except the comparison treatment), or to use
no treatment at all. Unspecific controls at point 3 (above) include
treatments that patients need to utilise, be it a very closely
defined single intervention or participation in a broad clinical
management programme. We will allow concomitant treatments
providing they are applied to both treatment conditions.
We will also accept trials on relaxation techniques, such as auto-
genic training or meditation regimens; and patient education pro-
grammes, such as self-management and community-based educa-
tion programs.
Types of outcome measures
Outcomes can either be self-rated by patients or observer-rated
by clinicians. We will include only adequately validated measures
(plus spontaneous reporting of adverse events).
We will analyse all outcomes at post-treatment and at six months’
follow-up or longer.
Primary outcomes
1. BPD severity, as assessed by, for example, the Zanarini
Rating Scale for Borderline Personality Disorder (Zan-BPD;
Zanarini 2003); the Borderline Personality Disorder Severity
Index, Fourth version (BPDSI-IV; Arntz 2003) or the Clinical
Global Impression Scale for Borderline Personality Disorder
Patients (CGI-BPD; Perez 2007).
2. Self-harm, in terms of proportion of participants with self-
harming behaviour, or as assessed by, for example, the Deliberate
Self-harm Inventory (DSHI; Gratz 2001) or the Self-harm
Behavior Questionnaire (SHBQ; Guttierez 2001).
3. Suicide-related outcomes, as assessed by, for example, the
Suicidal Behaviours Questionnaire (SBQ; Osman 2001) or the
Beck Scale for Suicidal Ideation (BSSI; Beck 1979), or in terms
of the proportion of patients with suicidal acts.
4. Functioning, as assessed by, for example, the Global
Assessment Scale (GAS; Endicott 1976), the Global Assessment
of Functioning Scale (GAF; APA 1987) or the Social
Functioning Questionnaire (SFQ; Tyrer 2005).
Secondary outcomes
1. Anger, as assessed by, for example, the “Hostility” subscale
of the Symptom Checklist-90-Revised (SCL-90-R; Derogatis
1994) or the State-Trait Anger Expression Inventory (STAXI;
Spielberger 1988).
2. Affective instability, as assessed by, for example, the relevant
item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD
(Perez 2007) or BPDSI-IV (Arntz 2003).
3. Chronic feelings of emptiness, assessed by, for example, the
relevant item or subscale on the Zan-BPD (Zanarini 2003),
CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003).
4. Impulsivity, as assessed by, for example, the Barrett
Impulsiveness Scale (BIS; Barrett 1995), or the Anger, Irritability
and Assault Questionnaire (AIAQ; Coccaro 1991).
5. Interpersonal problems, as assessed by, for example, the
Inventory of Interpersonal Problems (IIP; Horowitz 1988), or
the relevant item or subscale on the Zan-BPD (Zanarini 2003),
CGI-BPD (Perez 2007), BPDSI-IV (Arntz 2003), or SCL-90-R
(Derogatis 1994).
6. Abandonment, as assessed by, for example, the relevant
item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD
(Perez 2007) or BPDSI-IV (Arntz 2003).
7. Identity disturbance, assessed by, for example, the relevant
item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD
(Perez 2007) or BPDSI-IV (Arntz 2003).
8. Dissociation and psychotic-like symptoms, as assessed by,
for example, the Dissociative Experience Scale (DES; Bernstein
1986), or the Brief Psychiatric Rating Scale (BPRS; Overall
1962).
9. Depression, as assessed by, for example, the Beck
Depression Inventory (BDI; Beck 1961) or the Montgomery
Åsberg Depression Rating Scale (MADRS; Montgomery 1979).
10. Attrition, in terms of patients lost after randomisation in
each group.
11. Adverse effects, as measured by use of standardised
psychometric rating scales such as the Systematic Assessment for
Treatment Emergent Events (SAFTEE; Levine 1986), laboratory
values or spontaneous reporting. We define adverse events as
unfavourable outcomes that occur during or after psychotherapy
but are not necessarily caused by it (see Chapter 14 in the
Cochrane Handbook for Systematic Reviews of Interventions; Loke
2011). We will divide any reported adverse events into severe and
non-severe, according to the International Committee of
Harmonization guidelines (ICH 1996). Serious adverse events
are defined as any event that leads to death, is life-threatening,
requires inpatient hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability, and
any important medical event that may have jeopardised the
participant’s health or requires intervention to prevent it. All
other adverse events will be considered non-serious.
5Psychological therapies for people with borderline personality disorder (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search methods for identification of studies
Electronic searches
We will search the electronic databases and trials registers listed
below.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; current issue), in the Cochrane Library, which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register
2. MEDLINE Ovid (1948 onwards)
3. Embase Ovid (1980 onwards)
4. CINAHL EBSCOhost (Cumulative Index to Nursing and
Allied Health Literature; 1980 onwards)
5. PsycINFO Ovid (1806 onwards)
6. ERIC EBSCOhost (Education Resources Information
Center; 1966 onwards)
7. BIOSIS Previews Web of Science Clarivate Analytics (1969
onwards)
8. Web of Science Core Collection Clarivate Analytics (1900
onwards)
9. Sociological Abstracts ProQuest (1952 onwards)
10. LILACS (Latin American and Caribbean Health Science
Information database; lilacs.bvsalud.org/en)
11. OpenGrey (www.opengrey.eu)
12. Copac National, Academic and Specialist Library
Catalogue (COPAC; copac.jisc.ac.uk)
13. ProQuest Dissertations and Theses A&I (1743 onwards)
14. DART Europe E-Theses Portal (www.dart-europe.eu/basic-
search.php)
15. Networked Digital Library of Theses and Dissertations
(NDLTD; www.ndltd.org)
16. Australian New Zealand Clinical Trials Registry
(ANZCTR; www.anzctr.org.au/BasicSearch.aspx)
17. ClinicalTrials.gov (clinicaltrials.gov)
18. EU Clinical Trials Register (www.clinicaltrialsregister.eu/
ctr-search/search)
19. ISRCTN Registry (www.isrctn.com)
20. UK Clinical Trials Gateway (www.ukctg.nihr.ac.uk/
#popoverSearchDivId)
21. WHO International Clinical Trials Registry Platform
(ICTRP; who.int/ictrp/en)
The search strategy for MEDLINE is in Appendix 1 and we will
modify it for other databases using the appropriate syntax and
controlled terms. We will not limit our searches by language, year
of publication, or type of publication. We will seek translation of
the relevant sections of non-English language articles.
Searching other resources
We will handsearch relevant journals, including: the Journal of
Personality Disorders; the American Journal of Psychiatry; JAMA
Psychiatry; British Journal of Psychiatry; ACTA Psychiatrica Scan-
dinavica; Journal of the American Academy of Child and Ado-
lescent Psychiatry; Personality Disorders: Theory, Research and
Treatment; and the Journal of Clinical Psychiatry. Additionally,
we will contact researchers working in the field by email to ask for
unpublished data. We will also check abstracts of key conferences
for BPD (congresses of the European and the International So-
ciety for the Study of Personality Disorders; ESSPD and ISSPD
respectively) and will ask for any relevant unpublished data. We
will trace cross-references from relevant literature.
Data collection and analysis
We will conduct this review according to the guidelines set out
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a), and perform analyses using the latest version
of Review Manager 5 (RevMan 5), Cochrane’s statistical software
(Review Manager 2014).
Selection of studies
Six review authors (OJS, JMSW, BAV, JTM, MLK, SSN) will
work in three pairs and independently screen titles and abstracts
of all records retrieved by the searches; we will resolve uncertainty
or disagreement by consensus. For records that could be eligible
RCTs, we will obtain the full-text report and assess it for eligibility
based on the inclusion criteria (see Criteria for considering studies
for this review). The review authors will discuss disagreements,
and if they cannot reach an agreement, they will consult a third re-
view author (KL or ES).We will list apparently relevant RCTs that
do not fulfil the inclusion criteria with reasons for exclusion in the
’Characteristics of excluded studies’ tables.We will use Covidence
software to keep track of appraised trials and decisions. To ensure
transparency of study selection, we will provide flow charts ac-
cording to the QUOROM statement, showing how many records
have been excluded for a certain reason (Moher 1999).
Data extraction and management
All review authors will extract data. The review authors will work
in pairs and will complete the data collection form independently
to ensure accuracy. We will resolve disagreements by discussion or
by using an arbiter (ES) if required. OJS and JMSW will enter
data into RevMan 5 (ReviewManager 2014). In those cases where
there are not enough data or data are unclear in the published
trial reports, we will contact the study authors, requesting them to
supply the missing information. We will develop data extraction
forms to facilitate standardisation of data extraction.
Assessment of risk of bias in included studies
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All review authors will assess the risk of bias in each included study
using Cochrane’s tool for assessing risk of bias (Higgins 2017).
Data extractors will independently assign each trial to one of three
categories (low risk of bias, unclear (uncertain) risk of bias or high
risk of bias), according to guidelines provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
We will consider trials with one or more unclear or high risk of bias
domains as trials at high risk of bias overall andwill define trials that
have a low risk of bias in all domains to be at low risk of bias overall.
Given the risk of overestimating beneficial intervention effects
and underestimating harmful intervention effects in RCTs with
unclear or inadequate methodological quality (Kjaergard 2001;
Lundh 2012;Moher 1998; Savovi 2012a; Savovi 2012b; Schulz
1995; Wood 2008), we will also assess the influence of risk of
bias on our results (see Sensitivity analysis). We will call upon a
third review author (ES) to resolve any ongoing disagreements, if
necessary.
Considering bias due to lack of blinding is undoubtedly of impor-
tance, but it remains unclear how to best deal with this issue in re-
search practice (Boutron 2008). We have decided not to judge the
likelihood of detection bias due to inadequate blinding of patients
and personnel, because it is almost impossible to blind therapists
and patients in psychological therapy outcome research. We will,
however, assess the likelihood of detection bias due to inadequate
blinding of outcome assessors.
In accordance with Cochrane’s guidelines (Higgins 2017), we have
included other potential sources of bias as a final bias component.
Here, we will include the likelihood of performance bias due to
inadequate treatment adherence, the likelihood of bias due to dif-
ferent amounts of attention given to the treatment groups (atten-
tion bias), and other potential sources of bias.
The risk of bias components and the criteria for assigning judge-
ments of low, unclear or high risk of bias are shown in Appendix
4.
Measures of treatment effect
Continuous data
For continuous data, we will compare the mean score between the
two groups to give a mean difference (MD) and present this with
95%confidence intervals (CIs).Wewill use the overallMD,where
possible, to compare the outcome measures from trials. We will
estimate the standardised MD (SMD) where different outcome
measures are used to measure the same construct in the trials. We
will calculate SMDs on the basis of post-treatment results and, in
separate analyses, follow-up data.Wewill bundle follow-up data in
six-month steps. Where the direction of a scale is opposite to most
of the other scales, we will multiply the corresponding mean values
by −1 to ensure adjusted values. If the trials do not report means
and standard deviations but report other values like t-tests and P
values, we will try to transform these into standard deviations.
Dichotomous data
Wewill summarise dichotomous data as risk ratios (RR) with 95%
CIs. We will calculate the risk difference (RD) and the number
needed to treat for an additional beneficial outcome (NNTB) or
for an additional harmful outcome (NNTH) if there is a significant
effect of the intervention.
Unit of analysis issues
Repeated observations
We will calculate study estimates on the basis of post-treatment
group results. We will conduct separate analyses for data from dif-
ferent points of measurement (i.e. post-treatment, follow-up data
of six-months’ intervals, where we will use the last measurement
within these intervals). We will not use interim observations.
Cross-over trials
We plan to include data from randomised cross-over studies up to
the point of first cross-over (first period only) (Curtin 2002). We
will not consider outcomes from subsequent periods due to the
likelihood of carry-over effects from the preceding treatment(s).
We will not combine repeated participant observations in one
meta-analysis.
Cluster-randomised trials
Where trials have used cluster randomisation, we anticipate that
investigators will have presented their results after appropriately
controlling for clustering effects (robust standard errors or hierar-
chical linear models). If it is unclear whether a cluster-randomised
trial has used appropriate controls for clustering, we will contact
the investigators for further information. Where appropriate con-
trols have not been used, we will request and reanalyse individual
participant data using multilevel models that control for cluster-
ing. Following this, we will analyse effect sizes and standard errors
in RevMan 5 (Review Manager 2014), using the generic inverse
method (Higgins 2011b). If there is insufficient information to
control for clustering, we will enter outcome data into RevMan 5
using individuals as the units of analysis (Review Manager 2014),
and then conduct a sensitivity analysis to assess the potential bi-
asing effects of inadequately controlled cluster-randomised trials
(Donner 2002); see Sensitivity analysis. If individual participant
data are not available, we will look for information on intraclass
correlation coefficients to adjust for the potential clustering effects.
Adjustment for multiplicity
Wewill adjust the P values andCIs formultiplicity due to themany
secondary outcome comparisons following the method described
by Jakobsen 2014.
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Dealing with missing data
We will try to obtain any missing data, including incomplete out-
come data, by contacting trial authors. We will report this infor-
mation in the ’Risk of bias’ tables.
Wewill evaluate themethods used tohandle themissingdata in the
publications and to what extent it was likely that the missing data
influenced the results of outcomes of interest. We will calculate
effect sizes on the basis of ITT data, it that is possible. If only
available case analysis data are reported, we will calculate effect
sizes on this basis. Where dichotomous data are not presented on
the basis of ITT data, we will add the number of participants lost
in each group to the participants with unfavourable results, acting
on the assumption that most patients with BPD do not get lost at
random.
For continuous outcomes, we will discuss each trial’s methodology
for dealing with missing continuous data (e.g. last observation
carried forward or modified intention-to-treat approach). We will
use per protocol analysis, as available from the trial reports (that
is, results are based on the number of patients at follow-up).
If data are not reported in an immediately usable way and require
processing before being analysed, we will consult a statistician.
We will assess results derived from statistically processed data in
sensitivity analyses. See Sensitivity analysis.
Assessment of heterogeneity
Wewill assess studies for clinical homogeneity with respect to type
of therapy, therapy setting and control group. We will evaluate the
methodological heterogeneity by comparing the design of trials.
For any studies judged as homogeneous and adequate for pooling,
we will investigate statistical heterogeneity by both visual inspec-
tion of the graphs and the I² statistic (Higgins 2003). We will
judge I² values between 0% and 40% to indicate little heterogene-
ity, between 30% and 60% to indicate moderate heterogeneity,
between 50% and 90% to indicate substantial heterogeneity, and
between 75% and 100% to indicate considerable heterogeneity
(Deeks 2017). We will also assess statistical heterogeneity using
the Chi² test (P < 0.10) and report tau² an estimate of between-
study variance.
We intend to carry out meta-analyses even if there is substan-
tial concern about heterogeneity, but we will interpret the re-
sults with caution, and discuss possible reasons and investigate
themby conducting subgroup analyses. See Subgroup analysis and
investigation of heterogeneity.
Assessment of reporting biases
We will provide funnel plots for comparisons with sufficient pri-
mary studies and we will perform Egger’s statistical test for small-
study effects (Egger 1997). We will only use funnel plots if there
are 10 ormore studies in themeta-analysis, as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Sterne
2017).
Data synthesis
Wewill perform statistical analysis according to recommendations
in the latest version of the Cochrane Handbook for Systematic Re-
views of Interventions (Deeks 2017). In carrying out themeta-anal-
ysis, we will use the inverse-variance method, to give more weight
to more precise estimates from studies with less variance (mostly
larger studies). This minimises the imprecision of the pooled effect
estimate, and it is a common and simple approach to conducting
a meta-analysis (Deeks 2017). We will divide the doses and the
controls into different comparisons, ensuring that the treatment
comparisons will be comparable and homogeneous. We will use
the random-effects model for meta-analysis, since we expect some
degree of clinical heterogeneity to be present in most cases, though
not too substantial to prevent pooling in principle. For trials with
a high level of statistical heterogeneity, and where the amount of
clinical heterogeneity makes it inappropriate to use these trials in
meta-analyses, we will provide a narrative description of the trial
results. If data pooling seems feasible, we will pool the primary
studies’ effects and calculate their 95%CIs. If a trial provides more
than one measure for the same outcome construct (e.g. several
questionnaires for the assessment of depression), we will select the
one usedmost often in the whole pool of included studies for effect
size calculation, in order to minimise heterogeneity of outcomes
in form and content. If a study reports data of two assessment
instruments that are equally frequently used, two review authors
will discuss the issue and choose the one which is, in its content,
most appropriate for assessing BPD patients. We would prefer to
use observer-rated measures as the primary analysis.
Considering the various types of interventions identified by the
previous version of this review (Stoffers-Winterling 2012), we will
arrange the results according to classes of interventions, defined as
follows.
1. Individual psychotherapy
2. Group psychotherapy
3. Family therapy
4. Any combination of individual, family or group
psychotherapy
Psychotherapy will be defined as “treatment of mental illness or
emotional disturbances primarily by verbal or nonverbal commu-
nication” (NLM 2009).
Subgroup analysis and investigation of heterogeneity
We will conduct a subgroup analysis to make hypotheses about
the subgroups mentioned below.
1. Therapeutic schools (e.g. CBT, psychodynamic,
psychoeducation)
2. Age (15 to under 18 years of age, 18 to 50 years of age,
above 50 years of age)
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3. Sex (male versus female)
4. Comorbidity (patients with comorbidity versus patients
without comorbidity)
5. Treatment intensity (once a week compared to more than
once a week)
6. Duration (less than 6 months, 6 to 12 months and over 12
months)
7. Mode of therapy (individual compared to group therapy;
mixed therapy (i.e. a combination of individual and group
therapy, or a therapy not akin to individual or group therapy, e.g.
family therapy) compared to individual therapy; and mixed
therapy compared to group therapy
8. Setting (outpatient compared to inpatient)
9. Concurrent-drug interventions (trials with concurrent-drug
interventions compared to those without)
Heterogeneity-adjusted required information size
and Trial Sequential Analysis
Trial Sequential Analysis (TSA) is a methodology that combines
a required information size (RIS) calculation for a meta-analysis
with the threshold for statistical significance (Brok 2008; Brok
2009; Thorlund 2009; Wetterslev 2008). TSA is a tool for quan-
tifying the statistical reliability of the data in a cumulative meta-
analysis, adjusting P values for sparse data and for repetitive testing
on accumulating data (Brok 2008; Brok 2009; Thorlund 2009;
Wetterslev 2008).
Comparable to the a priori sample size estimation in a single ran-
domised trial, a meta-analysis should include an RIS calculation
at least as large as the sample size of an adequately powered single
trial to reduce the risk of random error. TSA calculates the RIS
in a meta-analysis and provides an alpha-spending boundary to
adjust the significance level for sparse data and repetitive testing
on accumulating data (CTU 2011; Wetterslev 2008); hence the
risk of random error can be assessed. Multiple analysis of accu-
mulating data when new trials emerge leads to repeated signifi-
cant testing and hence introduces multiplicity. Thus use of a con-
ventional P value is prone to exacerbate the risk of random error
(Berkey 1996; Lau 1995). Meta-analyses not reaching the RIS are
analysed with trial sequential alpha-spending monitoring bound-
aries analogous to interim monitoring boundaries in a single trial
(Wetterslev 2008). This approach will be crucial in coming up-
dates of the review. We will calculate an RIS on all outcomes in the
review. If a TSA does not reveal significant findings (no crossing of
the alpha-spending boundary and no crossing of the conventional
boundary of P = 0.05) before the RIS has been reached, then the
conclusion should either be that more trials are needed to reject
or accept an intervention effect that was used for calculation of
the required sample size or - in case the cumulated Z-curve en-
ters the futility area - the anticipated effect can be rejected. We
will calculate the a priori diversity-adjusted required information
size (that is, the number of patients required to detect or reject
a specific intervention effect in the meta-analysis), and perform
a TSA for the primary outcomes based on the following a priori
assumptions.
1. The standard deviation of the primary outcome is 1.0
2. An anticipated intervention effect equal to Hedge’s g of 0.5
3. A maximum type I error of 5% (alpha)
4. A maximum type II error of 20% (beta; equal to a
minimum 80% power)
5. A priori anticipated 50% diversity (Brok 2008; Brok 2009;
Thorlund 2009; Wetterslev 2008; Wetterslev 2009).
We will also calculate a post hoc, low bias, risk diversity-adjusted
required information size (that is, the number of patients required
to detect or reject a specific intervention effect in the meta-anal-
ysis), and perform a TSA for the primary outcomes based on the
following estimated assumptions.
1. The standard deviation of the primary outcome in patients
in the control group of trials with low risk of bias
2. The estimated intervention effect in trials with low risk of
bias
3. A maximum type I error of 5% (alpha)
4. A maximum type II error of 20% (beta; equal to a
minimum 80% power)
5. The estimated diversity in the trials included in the meta-
analysis (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev
2008)
’Summary of findings’ tables
We will use the GRADE approach to construct a ’Summary of
findings’ table in which to document all review outcomes. The
GRADE approach appraises the quality of a body of evidence
based on the extent to which one can be confident that an esti-
mate of effect or association reflects the item being assessed. Con-
siderations are due to: within-trial risk of bias; directness of the
evidence; heterogeneity of the data; precision of effect estimates;
and risk of publication bias (Andrews 2013a; Andrews 2013b;
Balshem 2011; Brunetti 2013; Guyatt 2011a; Guyatt 2011b;
Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f;
Guyatt 2011g; Guyatt 2011h; Guyatt 2013a; Guyatt 2013b;
Guyatt 2013c; Mustafa 2013). When possible, we will use the
MD or the RR, and we will use Trial Sequential Analysis (TSA)
to rate the imprecision (Jakobsen 2014). We will report the four
primary outcomes (BPD severity, self-harm, suicide-related out-
comes and functioning) and the three secondary outcomes (inter-
personal problems, attrition, and adverse events) in a ’Summary
of findings’ table for the main comparison (Atkins 2004).
Sensitivity analysis
We will assess the impact of heterogeneity on the overall pooled
effect estimate by removing studies (’outliers’) that are contribut-
ing to the heterogeneity. We will remove outliers one by one and
assess the impact on the overall outcome.
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Wewill conduct sensitivity analyses to determine whether findings
are sensitive to the following.
1. Decisions made during the review process (our assessment
of the level of clinical heterogeneity)
2. Impact of bias (studies with low and high risk of bias)
3. Type of model used for analysis (repeating the analysis
using the fixed-effect model to test the robustness of the results)
4. Type of data collection (for example, different ways to
measure depression)
5. Imputed data (comparing analyses with available outcome
data with those using an intention-to-treat (ITT) approach)
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A P P E N D I C E S
Appendix 1. DSM diagnostic criteria for BPD (301.83)
DSMThird Edition (DSM-III; APA 1980)
301.83 BPD
DSMFourthEditionTextRevision (DSM-
IV-TR; APA 2000)
301.83 BPD
DSM Fifth Edition (DSM-5; APA 2013)
301.83 BPD
Diagnostic criterion A
5 of the following are required
1. Impulsivity or unpredictability in at least
Diagnostic criterion A
A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
Diagnostic criterion A
A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
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(Continued)
2 areas that are potentially self-damaging (e.
g. spending, sex, substance use, shoplifting,
overeating, physically self-damaging acts)
2. A pattern of unstable and intense inter-
personal relationships (e.g. marked shifts of
attitude, idealization, devaluation, manip-
ulation (consistently using others for one’s
own ends))
3. Inappropriate, intense anger or lack of
control of anger (e.g. frequent displays of
temper, constant anger)
4. Identity disturbance manifested by un-
certainty about several issues relating to
identity, such as self-image, gender identity,
long-term goals or career choice, friendship
patterns, values, and loyalties (e.g. ’Who
am I’, ’I feel like I am my sister when I am
good’)
5. Affective instability, marked shifts from
normal mood to depression, irritability or
anxiety, usually lasting a fewhours and only
rarely more than a few days, with a return
to normal mood
6. Intolerance of being alone (e.g. frantic ef-
forts to avoid being alone, depressed when
alone)
7. Physically self-damaging acts (e.g. suici-
dal gestures, self-mutilation, recurrent ac-
cidents or physical fights)
8. Chronic feelings of emptiness or bore-
dom
fects, andmarked impulsivity beginning by
early adulthood and present in a variety of
contexts, as indicated by 5 (or more) of the
following
1. Frantic efforts to avoid real or imagined
abandonment (note: do not include sui-
cidal or self-mutilating behavior, which is
covered in criterion 5)
2. A pattern of unstable and intense inter-
personal relationships characterized by al-
ternating between extremes of idealization
and devaluation
3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of self
4. Impulsivity in at least 2 areas that are po-
tentially self-damaging (e.g. spending, sex,
substance abuse, reckless driving, binge eat-
ing) (note: do not include suicidal or self-
mutilating behavior, which is covered in
criterion 5)
5. Recurrent suicidal behavior, gestures, or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity of mood (e.g. intense episodic dys-
phoria, instability, or anxiety usually last-
ing a few hours and only rarely more than
a few days)
7. Chronic feelings of emptiness
8. Inappropriate, intense anger or difficulty
controlling anger (e.g. frequent displays of
temper, constant anger, recurrent physical
fights)
9. Transient, stress-related paranoid
ideation or severe dissociate symptoms
fects and marked impulsivity, beginning by
early adulthood and present in a variety of
contexts, as indicated by 5 (or more) of the
following
1. Frantic efforts to avoid real or imagined
abandonment (note: do not include sui-
cidal or self-mutilating behavior, which is
covered in criterion 5)
2. A pattern of unstable and intense inter-
personal relationships characterized by al-
ternating between extremes of idealization
and devaluation
3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of self
4 Impulsivity in at least 2 areas that are po-
tentially self-damaging (e.g. spending, sex,
substance abuse, reckless driving, binge eat-
ing) (note: do not include suicidal or self-
mutilating behavior, which is covered in
criterion 5)
5. Recurrent suicidal behavior, gestures or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity of mood (e.g. intense episodic dys-
phoria, irritability or anxiety of mood) usu-
ally lasting a fewhours and only rarelymore
than a few days
7. Chronic feelings of emptiness
8. Inappropriate, intense anger or difficulty
controlling anger (e.g. frequent displays of
temper, constant anger, recurrent physical
fights)
9. Transient, stress-related paranoid
ideation or severe dissociative symptoms
Diagnostic criterion B
If under 18, does not meet the criteria for
Identity Disorder
BPD: Borderline personality disorder; DSM: Diagnostic and Statistical Manual of Mental Disorders
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Appendix 2. ICD-10 research criteria for emotionally unstable personality disorder (F60.3)
F60.30: ICD-10 Emotionally unstable personality disorder,
impulsive type
F60.31: Emotionally unstable personality disorder, borderline
type
Diagnostic criterion A
The general criteria of personality disorder (F60) must be met
Diagnostic criterion A
The general criteria of personality disorder (F60) must be met
Diagnostic criterion B
At least 3 of the following must be present, 1 of which is 2
1. Marked tendency to act unexpectedly and without considera-
tion of the consequences
2. Marked tendency to quarrelsome behaviour and to conflicts
with others, especially when impulsive acts are thwarted or criti-
cized
3. Liability of outbursts of anger or violence, with inability to
control the resulting behavioural explosions
4. Difficulty in maintaining any course of action that offers no
immediate reward
5. Unstable and capricious mood
Diagnostic criterion B
At least 3 of the symptoms mentioned above in criterion B (F60.
30) must be present, and, in addition, at least 2 of the following
6. Disturbances in, and uncertainty about, self-image, aims and
internal preferences (including sexual)
7. Liability to become involved in intense and unstable relation-
ships, often leading to emotional crises
8. Excessive efforts to avoid abandonment
9. Recurrent threats or acts of self-harm
10. Chronic feelings of emptiness
ICD-10: International Classification of Diseases, Tenth Edition
Appendix 3. Medline search strategy
1 Borderline Personality Disorder/
2 ((borderline or border-line) adj3 (state* or personalit*)).kf,tw.
3 (“Axis II” or “Cluster B” or flamboyant or “F60.3” or “F60.30” or “F60.31”).kf,tw.
4 (idealization adj5 devaluation).kf,tw.
5 ((vulnerable or hyperbolic) adj3 temperament).kf,tw.
6 (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) adj3 (self* or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) and (personality or character or PD)).kf,tw.
7 (impulsiv* adj5 (behavio?r or character or personalit*)).kf,tw.
8 (self adj3 (injur* or damag* or destruct* or harm* or hurt* or mutilat*)).kf,tw.
9 (suicidal adj3 behavio?r).kf,tw.
10 (feel* adj3 (empt* or bored*)).kf,tw.
11 (anger adj5 control*).kf,tw.
12 (risk-taking adj3 behavio?r).kf,tw.
13 or/1-12
14 randomized controlled trial.pt.
15 controlled clinical trial.pt.
16 randomi#ed.ab.
17 placebo.ab.
18 randomly.ab.
19 trial.ab.
20 groups.ab.
21 drug therapy.fs.
22 or/14-21
23 exp Animals/ not Humans/
24 22 not 23
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Appendix 4. ’Risk of bias’ components and criteria for assigning judgements
Selection bias
Random sequence generation
1. Low risk of bias. The method used was adequate (e.g. computer-generated random numbers, table of random numbers) or was
unlikely to introduce selection bias.
2. Unclear risk of bias. Information was insufficient for assessment of whether the method used could introduce selection bias.
3. High risk of bias. The method used was likely to introduce bias.
Allocation concealment
1. Low risk of bias. The method used (e.g. central allocation) was unlikely to bias allocation to groups.
2. Unclear risk of bias. Information was insufficient for assessment of whether the method used could bias allocation to groups.
3. High risk of bias. The method used (e.g. open random allocation schedule) could bias allocation to groups.
Detection bias: Blinding of outcome assessment
1. Low risk of bias. The method of blinding was described and blinding was conducted in a satisfactory way.
2. Unclear risk of bias. Information was insufficient for assessment of whether the type of blinding used was likely to bias the
estimate of effect.
3. High risk of bias. No blinding or incomplete blinding.
Aattrition bias: Incomplete outcome data
1. Low risk of bias. Underlying reasons for missing data probably would not affect outcome measurement, as all missing data can
be considered as missing at random or all data were reported.
2. Unclear risk of bias. Information was insufficient for assessment of whether missing data or the method used to handle missing
data was likely to bias the estimate of effect.
3. High risk of bias. The crude estimate of effects could be biased given the reasons for the missing data, or the methods used to
handle missing data are unsatisfactory.
Reporting bias: Selective outcome reporting
1. Low risk of bias. The trial protocol was available and all pre-specified outcomes of interest were reported.
2. Unclear risk of bias. Information was insufficient for assessment of whether selective outcome reporting could have occurred.
3. High risk of bias. Not all of the primary outcomes specified beforehand were reported or participants were excluded after
randomisation.
Other potential sources of bias
Treatment adherence bias
1. Low risk of bias. Means were undertaken to assure adequate treatment adherence; for example, by regular supervision or use of
adherence ratings of videotaped or audio-taped therapy sessions.
2. Unclear risk of bias. Insufficient information to assess the extent of adequate treatment adherence.
3. High risk of bias. Inadequate treatment adherence. No means were undertaken to assure adequate treatment adherence.
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Attention bias
1. Low risk of bias. The treatment conditions were sufficiently similar in duration and intensity.
2. Unclear risk of bias. Insufficient information in regards to treatment duration and intensity.
3. High risk of bias. One treatment condition was markedly more intense or was of longer duration than other condition(s).
Affiliation bias
1. Low risk of bias. Principal investigator is not the developer of the treatment under investigation (if compared to a control
condition), or both treatment developers are involved if two treatments are directly compared.
2. Unclear risk of bias. Insufficient information to assess affiliation bias.
3. High risk of bias. Principal investigator is developer of the treatment under investigation (if compared to a control condition),
or only one of the treatment developers is involved if two treatments are directly compared.
Other sources of bias
1. Low risk of bias. The trial appeared to be free of other sources of bias.
2. Unclear risk of bias. Information was inadequate for assessment of other possible sources of bias.
3. High risk of bias. Other sources of bias were identified.
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